secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001493152-26-013095
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results
--------------------------------------------------------------------------------

- Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.
- Australia feasibility study started July 2025; findings are incorporated for planned US trial.
- Three US patents issued Oct/Nov 2025 covering sensor chemistry, intravascular lead, and low-power electronics.
- Expects to file IDE with FDA in Q2 2026 and initiate US clinical study in H2 2026, pending approval.
- Reinforced commercial foundation: market research, reimbursement pathway, dual-source manufacturing, seasoned leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226013095/0001493152-26-013095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226013095/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer